PT2194043E - Processos - Google Patents

Processos Download PDF

Info

Publication number
PT2194043E
PT2194043E PT101550580T PT10155058T PT2194043E PT 2194043 E PT2194043 E PT 2194043E PT 101550580 T PT101550580 T PT 101550580T PT 10155058 T PT10155058 T PT 10155058T PT 2194043 E PT2194043 E PT 2194043E
Authority
PT
Portugal
Prior art keywords
processes
Prior art date
Application number
PT101550580T
Other languages
English (en)
Inventor
Gerald J Tanoury
John E Cochran
Minzhang Chen
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PT2194043E publication Critical patent/PT2194043E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
PT101550580T 2005-08-19 2006-08-18 Processos PT2194043E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70996405P 2005-08-19 2005-08-19
US81004206P 2006-06-01 2006-06-01

Publications (1)

Publication Number Publication Date
PT2194043E true PT2194043E (pt) 2014-03-04

Family

ID=37708299

Family Applications (2)

Application Number Title Priority Date Filing Date
PT06813568T PT1934179E (pt) 2005-08-19 2006-08-18 PROCESSOS E INTERMEDIáRIOS
PT101550580T PT2194043E (pt) 2005-08-19 2006-08-18 Processos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT06813568T PT1934179E (pt) 2005-08-19 2006-08-18 PROCESSOS E INTERMEDIáRIOS

Country Status (25)

Country Link
US (3) US7776887B2 (pt)
EP (4) EP2364970A1 (pt)
JP (1) JP5203203B2 (pt)
KR (4) KR20140069370A (pt)
CN (2) CN102382170A (pt)
AR (1) AR058025A1 (pt)
AT (1) ATE463480T1 (pt)
AU (1) AU2006279357B2 (pt)
BR (1) BRPI0615029A2 (pt)
CA (1) CA2619659A1 (pt)
CY (2) CY1110214T1 (pt)
DE (1) DE602006013492D1 (pt)
DK (2) DK1934179T3 (pt)
ES (2) ES2449268T3 (pt)
HK (2) HK1122801A1 (pt)
IL (2) IL189585A (pt)
NZ (3) NZ566049A (pt)
PL (3) PL385229A1 (pt)
PT (2) PT1934179E (pt)
RU (2) RU2446171C2 (pt)
SG (1) SG2014013338A (pt)
SI (2) SI1934179T1 (pt)
TW (2) TWI391376B (pt)
WO (1) WO2007022459A2 (pt)
ZA (1) ZA200801791B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) * 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
MX2008001528A (es) * 2005-08-02 2008-04-04 Vertex Pharma Inhibidores de serina proteasas.
TWI391376B (zh) 2005-08-19 2013-04-01 Vertex Pharma 方法及中間物
US8399615B2 (en) * 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP2295401A3 (en) * 2006-03-16 2012-07-25 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
US20070225297A1 (en) 2006-03-16 2007-09-27 Perni Robert B Deuterated hepatitis C protease inhibitors
WO2008076316A2 (en) * 2006-12-15 2008-06-26 Schering Corporation Bisulfite purification of an alpha-keto amide
KR20090115970A (ko) * 2007-02-27 2009-11-10 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 그를 포함하는 제약 조성물
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
MX2010002407A (es) * 2007-08-30 2010-03-26 Vertex Pharma Cocristales y composiciones farmaceuticas que los comprenden.
WO2009114633A1 (en) * 2008-03-12 2009-09-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
US8143448B2 (en) 2008-06-13 2012-03-27 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
AU2009271325A1 (en) 2008-06-24 2010-01-21 Merck Sharp & Dohme Corp. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
MX2012009927A (es) * 2010-02-25 2012-10-05 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg Proceso para la preparacion de alfa-aciloxibeta-formamida amidas.
AU2011261349A1 (en) * 2010-06-03 2012-12-06 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN102167680B (zh) * 2011-03-23 2014-07-02 合亚医药科技（上海）有限公司 八氢环戊基并[c]吡咯羧酸衍生物的制备方法
CN103814001A (zh) * 2011-05-13 2014-05-21 弗特克斯药品有限公司 方法和中间体
WO2012158515A1 (en) * 2011-05-13 2012-11-22 Vertex Phamaceuticals Incorporated Process for the preparation of protease inhibitors
JP2013010738A (ja) * 2011-05-31 2013-01-17 Sumitomo Chemical Co Ltd エステル化合物の製造方法
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
CN103183632A (zh) * 2011-12-29 2013-07-03 山东方明药业集团股份有限公司 一种3-氮杂双环辛烷盐酸盐的提纯方法
ITMI20120192A1 (it) * 2012-02-13 2013-08-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
ITMI20120359A1 (it) 2012-03-07 2013-09-08 Dipharma Francis Srl Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali
ITMI20120391A1 (it) * 2012-03-13 2013-09-14 Dipharma Francis Srl Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali
WO2013136265A1 (en) 2012-03-13 2013-09-19 Dipharma Francis S.R.L. Synthesis of an intermediate of an antiviral compound
ITMI20121668A1 (it) * 2012-10-05 2014-04-06 Dipharma Francis Srl Sintesi di un intermedio di un composto antivirale
US20150038677A1 (en) 2012-03-16 2015-02-05 Sandoz Ag Process for the synthesis of telaprevir, or pharmaceutically acceptable salts or solvates as well as intermediate products thereof
ITMI20120608A1 (it) 2012-04-13 2013-10-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
ITMI20120800A1 (it) * 2012-05-10 2013-11-11 Dipharma Francis Srl Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali
AR091192A1 (es) 2012-05-30 2015-01-21 Chemo Iberica Sa Procedimiento multicomponente para la preparacion de compuestos biciclicos
CN103450066B (zh) * 2012-05-30 2017-03-15 博瑞生物医药（苏州）股份有限公司 特拉匹韦中间体的制备方法
ITMI20120990A1 (it) * 2012-06-07 2013-12-08 Dipharma Francis Srl Sintesi di un inibitore delle proteasi virali
WO2013189978A1 (en) 2012-06-20 2013-12-27 Sandoz Ag PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR
IN2014DN10328A (pt) 2012-06-20 2015-08-07 Sandoz Ag
WO2014019179A1 (zh) * 2012-08-01 2014-02-06 上海迪赛诺药业有限公司 特拉匹韦及其中间体的制备方法
WO2014033667A1 (en) 2012-08-30 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of telaprevir
CN102875648B (zh) * 2012-09-26 2014-02-19 深圳翰宇药业股份有限公司 一种制备特拉匹韦的方法
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
ITMI20122036A1 (it) 2012-11-29 2014-05-30 Dipharma Francis Srl Sintesi di un intermedio di un composto antivirale
US20160039871A1 (en) * 2012-12-21 2016-02-11 Sandoz Ag Novel forms of telaprevir
WO2014096374A1 (en) 2012-12-21 2014-06-26 Sandoz Ag Process for the synthesis of pyrrolidines and pyrroles
CN103936651B (zh) * 2013-01-18 2016-06-22 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅲ及其制备方法和应用
ITMI20130706A1 (it) * 2013-04-30 2014-10-31 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
CN103288671B (zh) * 2013-06-20 2014-10-29 上海步越化工科技有限公司 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法
WO2014203224A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and its intermediates
WO2014203208A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and intermediates thereof
CN104292146B (zh) * 2013-06-24 2017-04-26 上海医药工业研究院 特拉匹韦中间体及其制备方法
CN103342656B (zh) * 2013-07-04 2015-04-08 苏州永健生物医药有限公司 特拉匹韦中间体的合成方法
CN103435532B (zh) * 2013-09-02 2015-07-08 苏州永健生物医药有限公司 波普瑞韦中间体的合成方法
WO2015036522A1 (en) * 2013-09-13 2015-03-19 Sandoz Ag Process for the preparation and isolation of (s)-3-amino-n-cyclopropyl-2,2-dialkoxyhexanamide and (s)-tert-butyl(1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate and use thereof for the preparation of telaprevir
EP3060573B1 (en) 2013-10-23 2019-07-17 Kaneka Corporation Tetrapeptide compound and method for producing same
CN103664739B (zh) * 2013-12-10 2016-04-27 湖南科源生物制品有限公司 一种特拉匹韦中间体的制备方法
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN105646329A (zh) * 2014-11-28 2016-06-08 重庆圣华曦药业股份有限公司 一种制备特拉匹韦中间体的方法
CN105111129A (zh) * 2015-08-24 2015-12-02 上海合全药业股份有限公司 (1S,3aR,6aS)-八氢环戊烯并[C]吡咯-1-羧酸叔丁酯草酸盐的制备方法
CN105601556B (zh) * 2015-12-02 2018-11-13 镇江市高等专科学校 特拉匹韦双环吡咯烷中间体的制备方法
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
IL298324A (en) 2020-06-10 2023-01-01 Aligos Therapeutics Inc Antiviral compounds for the treatment of coronavirus, picornavirus and novovirus infections
KR20240035513A (ko) 2021-07-09 2024-03-15 알리고스 테라퓨틱스 인코포레이티드 항바이러스 화합물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
JPH0967344A (ja) * 1995-09-05 1997-03-11 Koei Chem Co Ltd 光学活性ｎ−ベンジルオキシカルボニルピペコリン酸の製造方法
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
JP3863230B2 (ja) 1996-08-16 2006-12-27 株式会社カネカ β−アミノ−α−ヒドロキシ酸誘導体の製造方法
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
HUP0100100A3 (en) * 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) * 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
WO2000055113A1 (en) 1999-03-12 2000-09-21 Ajinomoto Co.,Inc. PROCESS FOR THE PREPARATION OF α-AMINOKETONE DERIVATIVES
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
AU6371900A (en) 1999-07-26 2001-02-13 Du Pont Pharmaceuticals Company Lactam inhibitors of hepatitis c virus ns3 protease
JP2003525294A (ja) 2000-02-29 2003-08-26 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害剤
US6849599B2 (en) * 2000-03-08 2005-02-01 Rhode Island Hospital Combination drug therapy
WO2001074768A2 (en) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
JP4748911B2 (ja) * 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
MXPA02010375A (es) 2000-04-19 2003-04-25 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa del virus de la hepatitis c que comprenden porciones alquil y arilalanina p2.
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
JP4452441B2 (ja) 2000-07-21 2010-04-21 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
WO2002008244A2 (en) 2000-07-21 2002-01-31 Schering Corporation Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) * 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
DE60217114T2 (de) 2001-07-11 2007-10-25 Vertex Pharmaceuticals Inc., Cambridge Verbrückte bizyklische serinproteaseinhibitoren
NZ531681A (en) * 2001-10-24 2007-05-31 Vertex Pharma Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP1590442A4 (en) 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
PE20050953A1 (es) * 2003-09-26 2005-11-19 Schering Corp Compuestos macrociclicos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
US7365092B2 (en) 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2328589T3 (es) * 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
TWI391376B (zh) 2005-08-19 2013-04-01 Vertex Pharma 方法及中間物
US8258116B2 (en) 2007-05-04 2012-09-04 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection

Also Published As

Publication number Publication date
ES2449268T3 (es) 2014-03-19
DK2194043T3 (da) 2014-01-20
SI1934179T1 (sl) 2010-08-31
CA2619659A1 (en) 2007-02-22
PL1934179T4 (pl) 2014-03-31
TWI391376B (zh) 2013-04-01
IL228770A0 (en) 2013-12-31
DK1934179T3 (da) 2010-08-09
HK1145022A1 (en) 2011-03-25
ES2344156T3 (es) 2010-08-19
IL189585A (en) 2013-10-31
EP1934179A2 (en) 2008-06-25
PT1934179E (pt) 2010-07-12
US8637457B2 (en) 2014-01-28
KR20080047396A (ko) 2008-05-28
AR058025A1 (es) 2008-01-23
WO2007022459A3 (en) 2008-02-28
ATE463480T1 (de) 2010-04-15
EP2364970A1 (en) 2011-09-14
DE602006013492D1 (de) 2010-05-20
SI2194043T1 (sl) 2014-04-30
EP2194043A3 (en) 2010-11-24
RU2446171C2 (ru) 2012-03-27
NZ593214A (en) 2013-02-22
AU2006279357B2 (en) 2012-05-31
PL385229A1 (pl) 2008-09-29
KR101474405B1 (ko) 2014-12-23
ZA200801791B (en) 2008-12-31
AU2006279357A1 (en) 2007-02-22
RU2011148615A (ru) 2013-06-10
US7776887B2 (en) 2010-08-17
KR20140069370A (ko) 2014-06-09
TW200800889A (en) 2008-01-01
BRPI0615029A2 (pt) 2009-06-16
EP2194043A2 (en) 2010-06-09
US20070087973A1 (en) 2007-04-19
RU2008110479A (ru) 2009-09-27
US20100174077A1 (en) 2010-07-08
CN102382170A (zh) 2012-03-21
HK1122801A1 (en) 2009-05-29
CY1110214T1 (el) 2015-01-14
JP2009504780A (ja) 2009-02-05
IL189585A0 (en) 2008-08-07
CY1114916T1 (el) 2016-12-14
US20140107318A1 (en) 2014-04-17
PL1934179T3 (pl) 2010-09-30
WO2007022459A2 (en) 2007-02-22
KR20130038947A (ko) 2013-04-18
EP2194043B1 (en) 2013-12-25
EP2357170A1 (en) 2011-08-17
KR20130110236A (ko) 2013-10-08
NZ566049A (en) 2011-07-29
JP5203203B2 (ja) 2013-06-05
CN101291909B (zh) 2012-09-05
CN101291909A (zh) 2008-10-22
EP1934179B1 (en) 2010-04-07
TW201245149A (en) 2012-11-16
NZ604087A (en) 2014-07-25
SG2014013338A (en) 2014-06-27
PL2194043T3 (pl) 2014-07-31

Similar Documents

Publication Publication Date Title
HK1145022A1 (en) Processes
DE502006001600D1 (en) Pyrazolylcarboxanilide
DE602006018441D1 (en) Arabinofuranosidasen
DE602006018627D1 (en) Cholesterol-absorptionsinhibitor
DE602006017073D1 (en) Aspartylproteasehemmer
DE602006016093D1 (en) Cyanoanthranilamidinsektizide
DK1866498T3 (en) C-profil
EP1871379A4 (en) CYANOARYLAMINE
DE602006003064D1 (en) Tripeptid- und tetrapeptid-thioether
DE602006014261D1 (en) Benzimidazolverbindungen
DE602006009835D1 (en) Nthalten
DE602006009492D1 (en) Fluidmaschinen
DE602006016951D1 (en) 2-cyanoacrylatzusammensetzung
EP1951848A4 (en) VIESEL
DE502005007477D1 (en) Delta-sigma-modulator
EP1871655A4 (en) TRIGGER OPERATION FOR SIDE DRIVE
DE602006021065D1 (en) Lithium-batteriepack
EP1934350A4 (en) POLYOLÉOSINES
EP1871796A4 (en) VESICULINE
DE602006021558D1 (en) Modulare montgomery-multiplikationseinrichtung
EP1865780A4 (en) MINI OVEN
DE502006002219D1 (en) Rotationspumpe
DE602006015303D1 (en) Lecknachweisflicken
DE502006004337D1 (en) Strangführungsrolle
DE502006007734D1 (en) Thiazolcarbonsäureanilide